Journal
CURRENT OPINION IN OPHTHALMOLOGY
Volume 24, Issue 3, Pages 205-212Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/ICU.0b013e32835f8ec0
Keywords
bevacizumab; ranibizumab; vascular endothelial growth factor
Categories
Funding
- Alcon
- Allergan
- Novartis
- Genentech
- Bausch and Lomb
- Bayer
- Health Canada
- CIHR
Ask authors/readers for more resources
Purpose of review This study reviews differences in both ocular and systemic safety between intravitreal bevacizumab and ranibizumab in the setting of neovascular age-related macular degeneration. Recent findings Serious adverse events associated with either bevacizumab or ranibizumab injections are generally rare. However, acute intraocular inflammation (AII) tends to occur more frequently following bevacizumab injection. Systemic absorption of bevacizumab is greater than with ranibizumab, and many studies have shown an increased risk of systemic adverse events in patients receiving bevacizumab compared with those receiving ranibizumab. Summary Although rare, adverse events with off-label use of bevacizumab are more common than with ranibizumab. Continued study into long-term safety of the two agents is warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available